Dermatan Sulfate

coagulation factor II, thrombin ; Homo sapiens







120 Article(s)
Download
PMID
Title
Pub. Year
#Total Relationships
1 30869126 Recombinant dermatan sulfate is a potent activator of heparin cofactor II-dependent inhibition of thrombin. 2019 Jun 1 4
2 22419236 Dermatan sulfate: an alternative to unfractionated heparin for anticoagulation in hemodialysis patients. 2013 Jan-Feb 2
3 22987196 Alterations of fibrin network structure mediated by dermatan sulfate. 2013 Feb 2
4 23100275 Large inter-individual variation of the pharmacodynamic effect of anticoagulant drugs on thrombin generation. 2013 Apr 1
5 21732093 Longitudinal observations of serum heparin cofactor II-thrombin complex in treated Mucopolysaccharidosis I and II patients. 2012 Mar 1
6 22506762 A method to cleave target molecules in a neocartilage. 2012 1
7 21256835 The dermatan sulfate-dependent anticoagulant pathway is mostly preserved in aneurysm and in severe atherosclerotic lesions while the heparan sulfate pathway is disrupted. 2011 May 12 1
8 20670608 Glycosaminoglycan-binding properties and kinetic characterization of human heparin cofactor II expressed in Escherichia coli. 2010 Nov 15 2
9 18446715 Effects of dermatan sulfate for anticoagulation in continuous renal replacement therapy. 2008 Mar-Apr 2
10 18971786 Plasma heparin cofactor II activity is an independent predictor of future cardiovascular events in patients after acute myocardial infarction. 2008 Dec 1
11 16650906 Decreased heparin cofactor II activity is associated with impaired endothelial function determined by brachial ultrasonography and predicts cardiovascular events. 2007 Jan 8 1
12 17222891 Effect of oversulfated dermatan sulfate derivatives on platelet aggregation. 2007 2
13 16442510 Thrombin inhibition by antithrombin in the presence of oversulfated dermatan sulfates. 2006 Apr 10 1
14 16624894 N-Acetylgalactosamine 4,6-O-sulfate residues mediate binding and activation of heparin cofactor II by porcine mucosal dermatan sulfate. 2006 Aug 2
15 16038721 Adenovirus-mediated expression of heparin cofactor II inhibits thrombin-induced cellular responses in fibroblasts and vascular smooth muscle cells. 2005 1
16 14744972 High plasma heparin cofactor II activity is associated with reduced incidence of in-stent restenosis after percutaneous coronary intervention. 2004 Feb 3 2
17 15078125 Structural and conformational aspects of the anticoagulant and anti-thrombotic activity of heparin and dermatan sulfate. 2004 2
18 15148272 Heparin cofactor II is a novel protective factor against carotid atherosclerosis in elderly individuals. 2004 Jun 8 2
19 12818259 Additive thrombin inhibition by fast moving heparin and dermatan sulfate explains the anticoagulant effect of sulodexide, a natural mixture of glycosaminoglycans. 2003 Mar 15 2
20 12095635 Contribution of basic residues of the A helix of heparin cofactor II to heparin- or dermatan sulfate-mediated thrombin inhibition. 2002 Jul 3 4
21 12413592 Inhibition of a thrombin anion-binding exosite-2 mutant by the glycosaminoglycan-dependent serpins protein C inhibitor and heparin cofactor II. 2002 Jul 15 1
22 13679662 Dermatan sulphate as an antithrombotic drug. 2002 Sep-Dec 3
23 11294849 Molecular basis for the susceptibility of fibrin-bound thrombin to inactivation by heparin cofactor ii in the presence of dermatan sulfate but not heparin. 2001 Jun 15 5
24 11692908 [Calcium heparin-induced immunologic thrombocytopenia complicated with venous gangrene of the legs. Report of a clinical case]. 2001 Jul-Sep 1
25 11816710 Unbalanced effects of dermatan sulfates with different sulfation patterns on coagulation, thrombosis and bleeding. 2001 Nov 1
26 10749870 Altered dermatan sulfate structure and reduced heparin cofactor II-stimulating activity of biglycan and decorin from human atherosclerotic plaque. 2000 Jun 16 1
27 10093889 A rationale for targeting antithrombotic therapy at the vessel wall: improved antithrombotic effect and decreased risk of bleeding. 1999 Feb 12 1
28 10209287 Amino acid residues of heparin cofactor II required for stimulation of thrombin inhibition by sulphated polyanions. 1999 Apr 12 1
29 10349131 [Heparin cofactor II, a thrombin inhibitor with a still not clarified physiologic role]. 1999 2
30 10456450 Dermatan sulphate for the prevention of postoperative venous thromboembolism in patients with cancer. DOS (Dermatan sulphate in Oncologic Surgery) Study Group. 1999 Jul 1
31 10488098 Comparison of heparin- and dermatan sulfate-mediated catalysis of thrombin inactivation by heparin cofactor II. 1999 Sep 24 2
32 10494755 Hereditary homozygous heparin cofactor II deficiency and the risk of developing venous thrombosis. 1999 Sep 1
33 10907447 [New medical anticoagulants]. 1999 Nov 1
34 9485475 Ligand binding to thrombin exosite II induces dissociation of the thrombin-heparin cofactor II(L444R) complex. 1998 Mar 3 1
35 9692613 Anticoagulant dermatan sulfate proteoglycan (decorin) in the term human placenta. 1998 May 15 3
36 9774395 Highly sulfated dermatan sulfates from Ascidians. Structure versus anticoagulant activity of these glycosaminoglycans. 1998 Oct 23 1
37 9813026 Role of thrombin anion-binding exosite-I in the formation of thrombin-serpin complexes. 1998 Nov 20 1
38 9843172 Isolation of frog and chicken cDNAs encoding heparin cofactor II. 1998 Nov 2
39 8994426 Effect of nonspecific binding to plasma proteins on the antithrombin activities of unfractionated heparin, low-molecular-weight heparin, and dermatan sulfate. 1997 Jan 7 1
40 9068899 Mechanism of thrombin inhibition by heparin cofactor II in the presence of dermatan sulphates, native or oversulphated, and a heparin-like dextran derivative. 1997 Feb 2
41 9200333 Synthesis and biological effects of N-alkylamine-labeled low-molecular-mass dermatan sulfate. 1997 2
42 9353333 Inhibition of meizothrombin and meizothrombin(desF1) by heparin cofactor II. 1997 Nov 7 1
43 9394322 Individualized anticoagulation with dermatan sulphate for haemodialysis in chronic renal failure. 1997 Nov 2
44 8562924 Molecular and cellular basis for type I heparin cofactor II deficiency (heparin cofactor II Awaji). 1996 Feb 1 1
45 8603018 Thrombin-mediated activation of endogenous factor XI in plasma in the presence of physiological glycosaminoglycans occurs only with high concentrations of thrombin. 1996 Feb 2
46 8725717 The effects of dermatan sulfate at submicrogram/ml concentrations on in vitro thrombin generation. 1996 May 6
47 8792767 Arterial smooth muscle cell heparan sulfate proteoglycans accelerate thrombin inhibition by heparin cofactor II. 1996 Sep 1
48 8815580 The production of heparin cofactor II is not regulated by inflammatory cytokines in human hepatoma cells: comparison with plasminogen activator inhibitor type-1. 1996 Feb 1
49 7545318 Inhibition of thrombin by antithrombin III and heparin cofactor II in vivo. 1995 Mar 3
50 7588997 Effect of sulfated xylans during the interaction of [125I]-thrombin with antithrombin III or heparin cofactor II of human plasma. 1995 Jan-Mar 1